B. Braun Medical of Bethlehem, Pennsylvania, is recalling a lot of intravenous fluid after foreign particles were found in the solution, including cotton fibers, wood fiber, and polystyrene plastic. The recall covers Excel Lactated Ringers Injection in the 1,000 milliliter size and reaches hospitals and healthcare facilities nationwide and in Canada.
The company announcement posted by the FDA identifies the particulate as primarily cellulose cotton fibers, with individual particles also identified as cellulose wood fiber and polystyrene. B. Braun says it has received no reports of adverse events connected to this recall.
Lactated Ringers is one of the most routine products in a hospital. It is a sterile solution of water and electrolytes used for hydration and fluid replacement, and the company says it may be given to adult, pediatric, and neonatal patients based on clinical need.
The Reason Injectables Are Held to a Different Standard
A fiber swallowed with food passes through the digestive tract. A fiber infused into a vein does not.
Anything entering the bloodstream bypasses the barriers the body uses to filter what it takes in. The gut wall, stomach acid, and liver all screen substances that arrive by mouth. An intravenous line delivers material directly into circulation, where the only thing standing between a particle and the lungs is the diameter of the blood vessels it travels through.
B. Braun's risk statement is unusually specific about what that means. The company states that use of the defective product has a reasonable probability of causing pulmonary emboli, meaning blockages in the blood vessels of the lungs, along with occlusions of other blood vessels that can lead to tissue death and possible organ damage, and phlebitis, an inflammation of vein walls that may lead to clotting.
The systemic risks listed are broader still. Foreign particles infused intravenously can cause systemic activation of the immune system, organ dysfunction, and hemolysis, the breakdown of blood cells.
This is why manufacturers of injectable products operate under far stricter particulate limits than makers of oral medicines, and why a visible fiber in a bag of fluid is a recallable event while the same fiber in a food product might not be. The physical size of a particle matters as much as its composition, because capillaries in the lungs are narrower than a human hair.
The Timeline Is the Part Worth Noticing
The recalled lot was distributed between August 29 and September 30 of 2024, and it carries an expiration date of November 30, 2026.
That gap is the detail clinicians and hospital pharmacy staff should register. The product left the manufacturer nearly two years ago and remains within its labeled shelf life for another three months. A bag sitting in a supply room today is not obviously old, and nothing about its appearance would prompt a second look.
The recalled product can be identified by catalog number L7500, NDC 0264-7750-00, and lot number J4H077. It is packaged in a non-PVC, non-DEHP flexible container system.
This is also not B. Braun's first particulate recall of this product line. The company recalled two lots of a different Lactated Ringer's presentation in the spring over particles identified as cellulose and stearates with trace inorganic material, and a year earlier recalled two lots of Lactated Ringers and sodium chloride solutions for particulate found in the container. Each was a separate action with separate lots, and the current recall covers one lot only. But repeated cellulose findings across multiple recalls are the kind of pattern the FDA tracks across enforcement records.
What Patients and Families Should Understand
There is no consumer action here, and saying so plainly matters more than manufacturing urgency.
This product is not sold to the public. It goes to hospitals and healthcare facilities, which handle quarantine and return. Nobody has a bag of Lactated Ringers at home to check. B. Braun is notifying its distributors and customers by mail and arranging return and replacement.
Clinical staff is trained to inspect solutions before hanging a bag. In the company's earlier notices, B. Braun described the consequence of catching particulate before use as a minor delay while a replacement is obtained, rather than a risk to the patient. That inspection step is the reason most particulate problems never reach anyone.
There is a supply dimension worth naming, because IV fluid shortages have disrupted American hospitals repeatedly in recent years. A single-lot recall of a widely used product does not by itself create a shortage, and nothing in this notice suggests one. But hospitals operating on thin margins of basic supplies have less room to absorb even small withdrawals.
Anyone who has received IV fluids recently and is worried can raise it with their clinician, but there is no symptom to watch for that would be specific to this recall. Signs of a problem with any IV line, including pain, swelling, redness or hardness along the vein, warrant telling a nurse regardless of any recall. Sudden shortness of breath or chest pain after an infusion requires urgent evaluation. This article is general information and is not a diagnosis.
Hospital pharmacy and supply chain staff should check inventory against lot J4H077 and follow the return process. Adverse reactions or quality problems can be reported through FDA MedWatch, and the agency posts all drug recalls to its recalls and safety alerts index. B. Braun can be reached at recalls@bbraunusa.com. The FDA had not assigned a risk classification to this recall as of publication, and that determination typically follows in an enforcement report.
Key Questions Answered
What was recalled? One lot of B. Braun Excel Lactated Ringers Injection, 1,000 mL, catalog number L7500, NDC 0264-7750-00, lot J4H077, with an expiration date of November 30, 2026.
What was found in it? Particulate matter identified primarily as cellulose cotton fibers, with individual particles also identified as cellulose wood fiber and polystyrene.
Why is this dangerous? The company says particles infused into a vein can block blood vessels in the lungs or elsewhere, inflame vein walls, activate the immune system, cause organ dysfunction, or break down blood cells.
Has anyone been harmed? B. Braun says it has received no reports of adverse events related to this recall.
Do consumers need to check anything at home? No. The product was distributed to hospitals and healthcare facilities, not to the public.
Why is a two-year-old lot being recalled now? The lot shipped between August and September of 2024 and does not expire until November 30, 2026, so it can still be in hospital inventory and within its labeled shelf life.
What should hospital staff do? Check inventory against lot J4H077, stop use, quarantine the product, and follow B. Braun's return and replacement process. Quality problems can be reported through FDA MedWatch.
